X4 Pharmaceuticals Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scroll to see more
X4 Pharmaceuticals, Inc. income statement - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Revenue & Gross Profit
Revenue2.560.000.000.003.00
Cost of Revenue0.800.000.000.000.00
Gross Profit1.760.000.000.003.00
Operating Expenses
Research & Development81.6472.0261.0650.6541.93
Selling, General & Administrative61.5235.5127.0224.7020.94
Operating Expenses143.16107.5288.0875.3562.87
Operating Income-141.40-107.52-88.08-75.35-59.87
Other Income/Expense
Interest Income5.774.580.220.010.27
Interest Expense8.775.78-3.99-3.64-2.69
Other Income/Expense107.267.63-2.500.064.84
Income
Income Before Tax-37.14-101.09-93.84-88.68-61.98
Income Tax Expense0.310.080.030.020.15
Net Income-37.45-101.17-93.87-88.70-62.13
Net Income - Continuous Operations-37.45-101.17-93.87-88.700.00
Net Income - Discontinued Operations0.000.000.000.000.00
EBITDA-27.58-94.89-87.57-74.85-59.52
EBIT-28.37-95.31-88.08-75.35-59.87
Depreciation & Amortization0.800.420.510.500.35
Earnings Per Share
Basic EPS-6.00-17.00-46.00-120.00-93.00
Diluted EPS-6.00-17.00-46.00-120.00-93.00
Basic Shares Outstanding6.705.932.120.860.67
Diluted Shares Outstanding6.705.932.120.860.67